BR112012004304A2 - quinolinas condensadas como moduladores de proteína cinase. - Google Patents
quinolinas condensadas como moduladores de proteína cinase.Info
- Publication number
- BR112012004304A2 BR112012004304A2 BR112012004304A BR112012004304A BR112012004304A2 BR 112012004304 A2 BR112012004304 A2 BR 112012004304A2 BR 112012004304 A BR112012004304 A BR 112012004304A BR 112012004304 A BR112012004304 A BR 112012004304A BR 112012004304 A2 BR112012004304 A2 BR 112012004304A2
- Authority
- BR
- Brazil
- Prior art keywords
- quinolines
- condensed
- protein kinase
- kinase modulators
- modulators
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 150000003248 quinolines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23722709P | 2009-08-26 | 2009-08-26 | |
| US28931709P | 2009-12-22 | 2009-12-22 | |
| PCT/US2010/046760 WO2011025859A1 (en) | 2009-08-26 | 2010-08-26 | Condensed quinolines as protein kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012004304A2 true BR112012004304A2 (pt) | 2016-03-15 |
Family
ID=42983433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012004304A BR112012004304A2 (pt) | 2009-08-26 | 2010-08-26 | quinolinas condensadas como moduladores de proteína cinase. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110065698A1 (enExample) |
| EP (1) | EP2470544A1 (enExample) |
| JP (1) | JP2013503178A (enExample) |
| KR (1) | KR20120059571A (enExample) |
| CN (1) | CN102596969A (enExample) |
| AU (1) | AU2010286691A1 (enExample) |
| BR (1) | BR112012004304A2 (enExample) |
| CA (1) | CA2771890A1 (enExample) |
| IL (1) | IL218280A0 (enExample) |
| IN (1) | IN2012DN02596A (enExample) |
| MX (1) | MX2012002426A (enExample) |
| SG (1) | SG178552A1 (enExample) |
| WO (1) | WO2011025859A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EP3648606A1 (en) * | 2017-07-03 | 2020-05-13 | Bayer CropScience Aktiengesellschaft | Novel substituted isothiazolopyridones, processes for their preparation and their use as herbicides and/or plant growth regulators |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| GB202213166D0 (en) * | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| GB202213163D0 (en) * | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| ATE339406T1 (de) | 1999-09-23 | 2006-10-15 | Astrazeneca Ab | Chinazoline verbindungen als heilmittel |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| KR20070114748A (ko) | 2005-02-17 | 2007-12-04 | 에이엠알 테크놀로지, 인크. | Ｃｉｎｖ 및 ｉｂｓｄ를 치료하기 위한 벤족사졸카복스아미드 |
| US7956064B2 (en) * | 2006-09-01 | 2011-06-07 | Cylene Pharmaceuticals, Inc. | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators |
| CN102036561A (zh) * | 2008-02-29 | 2011-04-27 | 赛林药物股份有限公司 | 蛋白激酶调节剂 |
| KR20110095857A (ko) * | 2008-09-10 | 2011-08-25 | 칼립시스, 인코포레이티드 | 질환의 치료를 위한 히스타민 수용체의 헤테로시클릭 억제제 |
| TW201204727A (en) * | 2010-03-10 | 2012-02-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
-
2010
- 2010-08-26 IN IN2596DEN2012 patent/IN2012DN02596A/en unknown
- 2010-08-26 AU AU2010286691A patent/AU2010286691A1/en not_active Abandoned
- 2010-08-26 WO PCT/US2010/046760 patent/WO2011025859A1/en not_active Ceased
- 2010-08-26 BR BR112012004304A patent/BR112012004304A2/pt not_active Application Discontinuation
- 2010-08-26 JP JP2012526972A patent/JP2013503178A/ja active Pending
- 2010-08-26 KR KR1020127007386A patent/KR20120059571A/ko not_active Withdrawn
- 2010-08-26 MX MX2012002426A patent/MX2012002426A/es not_active Application Discontinuation
- 2010-08-26 CN CN2010800474008A patent/CN102596969A/zh active Pending
- 2010-08-26 CA CA2771890A patent/CA2771890A1/en not_active Abandoned
- 2010-08-26 EP EP10749732A patent/EP2470544A1/en not_active Withdrawn
- 2010-08-26 SG SG2012012845A patent/SG178552A1/en unknown
- 2010-08-26 US US12/869,335 patent/US20110065698A1/en not_active Abandoned
-
2012
- 2012-02-23 IL IL218280A patent/IL218280A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102596969A (zh) | 2012-07-18 |
| US20110065698A1 (en) | 2011-03-17 |
| KR20120059571A (ko) | 2012-06-08 |
| IL218280A0 (en) | 2012-04-30 |
| SG178552A1 (en) | 2012-03-29 |
| JP2013503178A (ja) | 2013-01-31 |
| AU2010286691A1 (en) | 2012-04-19 |
| CA2771890A1 (en) | 2011-03-03 |
| IN2012DN02596A (enExample) | 2015-08-28 |
| WO2011025859A1 (en) | 2011-03-03 |
| MX2012002426A (es) | 2012-06-27 |
| EP2470544A1 (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012004304A2 (pt) | quinolinas condensadas como moduladores de proteína cinase. | |
| BR112012004718A2 (pt) | compostos como moduladores de tirosina quinase | |
| BRPI1008939A2 (pt) | 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3. | |
| EP2447175A4 (en) | RETORTE CUP | |
| FR2947261B1 (fr) | Zircone frittee coloree. | |
| BR112012010640A2 (pt) | novos moduladores de quinase | |
| BRPI1013760A2 (pt) | compostos anticâncer de amino pirimidina. | |
| BRPI1013688A2 (pt) | proteínas de ligação de il-17. | |
| BRPI1011965A2 (pt) | estrutura de entressola. | |
| BRPI0919390A8 (pt) | quinazolinone, quinolone e análogos relacionados como muduladores sirtuinais. | |
| BRPI1007047A2 (pt) | Biorrefino irganosolv de cana-de-açúcar inteira. | |
| BRPI1011694A2 (pt) | similadores de categoria | |
| BRPI0919898A2 (pt) | 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3 | |
| BR112013013548A2 (pt) | proteína de fusão anticancerígena | |
| BRPI1014388A2 (pt) | preparação de sólido. | |
| BR112012001305A2 (pt) | protetor de pavimentação. | |
| IT1396487B1 (it) | Convogliatore. | |
| BRPI1013799A2 (pt) | eletrodos de desfibrilação. | |
| BRPI1016192A2 (pt) | derivados de soxazol. | |
| BRPI1014897A8 (pt) | dispositivo de suspensão. | |
| BRPI1009519A2 (pt) | 3-amino-2-mercaptoquinolina substituída como modulador de kcnq2/3. | |
| BRPI1013966A2 (pt) | microensaio de esterilidade rápida. | |
| BR112012000565A2 (pt) | ensaio de vírus. | |
| BR112012014495A2 (pt) | cosmético de autonivelamento. | |
| FR2943510B1 (fr) | Ombrelle. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |